Advanced Medical Optics (EYE)

Item 7.01.     Regulation FD Disclosure

As a result of the additional plan to reduce fixed costs described above, AMO expects to achieve net savings in 2009 of approximately $10 - $15 million as compared to 2008 spending levels. These savings are expected to be realized across both operating expenses and cost of goods sold. This disclosure under Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Item 7.01. Regulation FD Disclosure.

Advanced Medical Optics, Inc. (“AMO,” “we”, “us” or “our”) is furnishing certain supplemental information concerning AMO and its previously announced acquisition by merger of IntraLase Corp. This supplemental information is set forth in Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The supplemental information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.

RATIO OF EARNINGS TO FIXED CHARGES

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX